ClinicalTrials.Veeva

Menu
T

Triad Clinical Trials | Greensboro, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Simufilam
AR1001
CIN-102
ALZ-801
Deudomperidone
mRNA-1345
ALZ- 801
MTX
DFV890

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 10 total trials

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV8...

Enrolling
Coronary Heart Disease
Drug: DFV890
Drug: Placebo

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling
Gout
Drug: Methotrexate
Biological: Pegloticase

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. Th...

Active, not recruiting
Early Alzheimer's Disease
Drug: Experimental: ALZ-801
Drug: Placebo Comparator: Placebo

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Invitation-only
Early Alzheimer's Disease
Drug: Experimental: ALZ-801

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only
Alzheimer Disease
Drug: Simufilam
Locations recently updated

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: AR1001

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

Trial sponsors

A
C
Amgen logo
A
C
Lilly logo
Moderna logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems